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Abbreviations/ Acronyms:  
ACQ-6 Asthma control questionnaire 6 
AOS Airwave oscillometry 
AX Area under the reactance curve 
BDP Beclomethasone dipropionate 
CI Confidence interval 
FeNO Fractional exhaled nitric oxide 
FEV1 Forced expiratory volume in 1 second 
FEF25-75 Forced expiratory flow at 25-75% of pulmonary volume  
FOT Forced oscillation technique 
ICS Inhaled corticosteroids 
IOS Impulse oscillometry 
LABA Long-acting beta agonist 
LAMA Long-acting muscarinic antagonist 
LTRA Leukotriene receptor antagonist 
mAQLQ Mini asthma quality of life questionnaire 
PRO Patient reported outcomes 
R5 Resistance at 5 Hz 
R5-R19 Difference between resistance at 5 Hz and 19 Hz  
R5-R20 Difference between resistance at 5 Hz and 20 Hz  
SAD Small airway dysfunction 





Airwave oscillometry (AOS: Tremoflo, Thorasys, Montreal) is a modern forced oscillation technique (FOT) 
using a vibrating mesh to superimpose forced oscillations of sound waves on top of normal tidal breathing 
to measure respiratory impedance as lung resistance (R) and reactance (X), whereas the older impulse 
oscillometry (IOS: Jaeger Masterscreen, Carefusion Hoechberg, Germany) uses a loudspeaker source. AOS 
measurements strongly correlate with IOS 1, 2 and quantify the degree of small airways dysfunction (SAD) 
as either peripheral airway resistance in terms of heterogeneity (AOS: R5-R19; IOS: R5-R20) or peripheral 
reactance (i.e. compliance) as area under the reactance curve (AX).  
In asthmatics with a preserved forced expiratory volume in 1 second (FEV1), the presence of SAD as 
measured with an increase in R5-R20 was associated with significantly higher long term oral corticosteroid 
and inhaled salbutamol use.3 In more severe, poorly controlled asthma patients, IOS measurements of 
R5-R20 and AX, but not spirometry (FEV1), were more closely related to disease activity as measured by 
asthma control questionnaire (ACQ-6).4 The fractional exhaled breath nitric oxide (FeNO) is a non-invasive 
surrogate for type 2 (T2) airway inflammation which relates to airway hyper-responsiveness. SAD asthma 
phenotype is an individual with normal FEV1 and increased R5-R20. We have reported that the SAD 
phenotype is related to an increased blood eosinophil count.5  
We therefore investigated the relationship of AOS to patient reported outcomes (PRO) of asthma control, 
namely ACQ-6 and mini asthma quality of life questionnaire (mAQLQ). In particular, we were interested 
in ACQ-6 which is a strong predictor of future exacerbation risk.6, 7  
Retrospectively, we evaluated a cohort of 46 adult patients with persistent asthma who voluntarily 
attended our centre for clinical trial screening into clinical trials. This was a completely different cohort to 
that previously reported using IOS.5 AOS and spirometry (Micromedical, Chatham, United Kingdom) were 
performed in triplicate according to European Respiratory Society guidelines and spirometry was always 
done after the AOS measurements. Consents were obtained from all patients for their screening data to 
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be accessed.  Comparisons of ACQ-6, AOS and pre-bronchodilator spirometry were analysed with each 
predefined cut point value: R5-R19 (kPa/L/s) <0.08 vs ≥0.08 8, AX (kPa/L) <1.0 vs ≥1.0; FEV1 (% predicted) 
<80 vs ≥80; FEF25-75 (% predicted) <50 vs ≥50. Differences in percent reversibility of AOS and spirometry 
following inhaled salbutamol 400µg were compared between well and poorly controlled asthma defined 
by ACQ-6 of <0.75 and ≥1.5 respectively. FeNO data were log-transformed to normalise the distribution. 
Unpaired Student’s t tests was used to compare each outcome with alpha error set at 0.05 (2-tailed).    
The overall mean age was 51 years, FEV1 87% predicted, R5 142%, inhaled corticosteroid (ICS) 
beclometasone dipropionate (BDP) equivalent of 620µg, 65 % were taking long-acting beta agonist (LABA), 
11% long-acting muscarinic antagonist (LAMA) and 37% leukotriene receptor antagonist (LTRA). Using a 
cut point for R5-R19 of 0.08 kPa/L/s, there were differences in mean ACQ-6 values: 1.01 vs 2.07 (95% CI 
for difference -1.66, -0.45; p<0.01) (Fig 1) and in mAQLQ (symptoms): 5.23 vs 4.30 (CI 0.10, 1.74; p<0.05). 
For AX with a cut point of 1.0 kPa/L there were differences in ACQ-6: 0.99 vs 1.93 (CI -1.55, -0.33; p<0.01), 
in mAQLQ symptoms: 5.28 vs 4.42 (CI 0.06, 1.66; p<0.05) and mAQLQ activity: 5.92 vs 5.01 (CI 0.004, 1.81; 
p<0.05). For the R5-R19 there was also a difference in geometric mean FeNO (ppb): 30 vs 45 (CI 25 - 38%; 
p<0.05).  
For FEV1 cut point of 80% predicted, differences were seen in ACQ-6: 2.20 vs 1.27 (CI 0.11, 1.76; p<0.05) 
and mAQLQ symptoms: 4.05 vs 5.09 (CI -1.93, -0.16; p<0.05) but not FeNO. For FEF25-75 cut point of 50% 
predicted there were differences in ACQ-6 1.90 vs 1.23 (CI 0.003, 1.34; p<0.05) and geometric mean of 
FeNO 47 vs 30 ppb (CI 29 – 170%; p<0.05). 
In a subgroup of 30 asthmatic patients with preserved FEV1 ≥80%, using ACQ-6 cut point of <1 vs ≥1 
defining poor asthma control, there were significant differences in AOS measurements for R5: 0.37 vs 0.46 
kPa/L/s (CI 0.01, 0.18; p<0.05), R5-R19: 0.05 vs 0.12 kPa/L/s (CI 0.01, 0.14; p<0.05) and AX: 0.88 vs 2.06 
kPa/L (CI 0.04, 2.32; p<0.05).  
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For ACQ-6 using a cut point of <0.75 vs ≥0.75, there were differences in mean percent reversibility for R5: 
11 vs 24% (CI -22, -5; p<0.01) and R5-19: 18 vs 51% (CI -60, -6; p<0.05), but not for FEV1 (p=0.05). For ACQ-
6 at a cut point of <1.5 vs ≥1.5, differences were observed in percent reversibility for R5: 15 vs 25% (CI -
18, -2; p<0.05), R5-19: 27 vs 55% (CI -53, -3; p<0.05) and FEV1: 5 vs 10% (CI -7, -1; p<0.05).   
Our results show asthmatic patients with SAD defined by R5-R19 or AX have significantly poorer asthma 
control and quality of life in terms of symptoms. Our findings are similar to those of Foy et al8 who also 
reported good correlations between R5-R20 (IOS) and asthma control using patient based computational 
modelling. However, another study concluded that IOS has no discriminative capacity to classify patients 
according to the degree of asthma control.9 In the present study, we used a lower cut off for AX of 1.0 
kPa/L using AOS as compared to 1.5 kPa/L using IOS in a previous study.5 The reason for this is that AOS is 
more sensitive than IOS in detecting altered lung compliance.2 
We observed that the degree of bronchodilator reversibility was relatively greater with AOS than 
spirometry. Notably, for an ACQ-6 cut point of 0.75 there was a statistically significant difference in ACQ-
6 for R5 and R5-R19 but not FEV1. This finding is consistent with a previous study comparing reversibility 
of IOS and spirometry in asthma in terms of relative bronchodilation and bronchoconstriction. Hence, AOS 
may be more sensitive  for detecting reversibility in patients with a preserved FEV1 where there is little 
room for improvement.10 
The main limitation of our study is that the data were retrospective and cross-sectional. A prospective 
serial evaluation might be able to better correlate AOS with PRO. We utilised FeNO as a surrogate measure 
of type 2 airway inflammation but did not measure sputum eosinophils. It would be helpful to perform a 
prospective evaluation of the utility of AOS to predict exacerbations although this has already been 
documented retrospectively by Manoharan et al 3 over two years. 
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In conclusion, peripheral lung resistance and reactance measured by AOS are related to patient reported 
outcomes of asthma control and quality of life. AOS was also more sensitive at detecting bronchodilator 
reversibility in relation to asthma control. We propose that measuring AOS should complement 
spirometry as part of the routine work up of asthma patients in a real life clinic setting. 
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ACQ values are shown as means and SEM for significant comparisons according to R5-R19, AX, FEV1 % 
predicted and FEF25-75 % predicted. 
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Figure 1 
 
